New data independently confirms and extends laboratory findings and expands safety profile of ATH434-PR Newswire APAC
- Written by PR Newswire Asia - Daily Bulletin Au RSS

MELBOURNE, Australia and SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of...